TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Histologically Confirmed Metastatic, or Recurrent Breast Cancer~* Age over 18 Years~* ECOG Performance Status 0-2~* Premenopausal or Postmenopausal Breast Cancer Patients With Measurable or Non-Measurable Lesions, Who Are Candidates for Chemotherapy~* Life Expectancy ≥ 3 Months~* Patients May Have Received Prior Neoadjuvant or Adjuvant Taxane Regimen as Long as it Has Been 12 Months Since Completion of Regimen.~* Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.~* Prior Hormonal Therapy as a Treatment of Metastatic Disease is Allowed. But Antitumoral Hormonal Therapy Must be Terminated Prior to Enrollment(up to the Date of Randomization)~* Prior Radiation Therapy Allowed as Long as \< 25% of the Bone Marrow Has Been Treated,and the Patients Must Have Recovered From the Acute Toxic Effects of the Treatment Prior to Study Enrollment.Prior Radiation to the Whole Pelvis is Not Allowed. Prior Radiotherapy Must be Completed 4 Weeks Before Study Entry.~* Adequate Bone Marrow Function (≥ ANC 1,500/ul, ≥ Platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl)~* Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)~* Adequate Liver Function (≤ Serum Bilirubin 1.5 mg/dl, ≤ AST/ALT x 3 Upper Normal Limit)~* No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer~* Written Informed consent.~Exclusion Criteria~* Serious Uncontrolled Intercurrent Infections~* Serious Intercurrent Medical or Psychiatric Illness, Including Active Cardiac Disease~* Pregnancy or Breast Feeding~* Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)~* Documented Parenchymal or Leptomeningeal Brain Metastasis~* Peripheral Neuropathy ≥ Grade 2~* Prior Treatment With Gemcitabine Will Not be Allowed.~* HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: NO_INTERVENTION): Observation after 6 cycles of gemcitabine plus paclitaxel till progression
- Arm 2 (Type: EXPERIMENTAL): Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of gastric cancer~* Chemonaive patients~* Adequate organ function~Exclusion Criteria:~* Patients who meet the contra-indications of S-1 and Cisplatin.~* Prior chemotherapy failure patients

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Exenatide in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~\*\*\*Subjects must be patients of the Texas Children's Hospital Diabetes Care Center\*\*\*.~All of the following criteria must be met:~1. Between 12-21 years of age at the time of enrollment.~2. Have been diagnosed with Type 1 diabetes for at least 1 year and in good control (HbA1C less than 8.5%).~3. Subjects must be otherwise healthy except for the Type 1 Diabetes and treated hypothyroidism.~4. Menstruating women must have a negative pregnancy test.~5. Hemoglobin equal to or greater than 12 g/dL before each study.~6. Weight greater than 44 kg.~7. Tanner stage greater than 3~Exclusion Criteria:~1. Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis etc or on treatment that might directly or indirectly affect glucose homeostasis, except for diabetes and hypothyroidism; stable on medications.~2. Lack of a supportive family environment as detected by the clinicians and/or social workers.~3. Positive pregnancy test in menstruating young women.~4. BMI greater than 90th percentile for age or less than 10th percentile for age.~5. Lactating and nursing mothers.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide 1.25 mcg + Insulin (Type: EXPERIMENTAL): In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
- Exenatide 2.5 mcg + Insulin (Type: EXPERIMENTAL): In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
- Insulin (Type: ACTIVE_COMPARATOR): Each subject received a baseline study with insulin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 1 to \< 12 years at randomization (Day 1).~* Written informed consent/assent for study participation obtained from participant's parents or legal guardian, with assent as appropriate by the participant, depending on the patient's level of understanding~* Participant able to comply with study requirements, depending on the patient's level of understanding~* Participant with a diagnosis of influenza virus infection confirmed by the presence of all of the following:~* Fever ≥ 38 degree celsius (tympanic temperature) at screening~* At least one respiratory symptom (either cough or nasal congestion)~* The time interval between the onset of symptoms and screening is ≤ 48 hours~Exclusion Criteria:~* Severe symptoms of influenza virus infection requiring inpatient treatment~* Concurrent infections requiring systemic antiviral therapy at screening~* Require, in the opinion of the investigator, any of the prohibited medication during the study~* Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening~* Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to randomization~* Concomitant treatment with steroids or other immuno-suppressant therapy~* Known HIV infection or other immunosuppressive disorder~* Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure.~* Active cancer at any site~* History of organ transplantation~* Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to acetaminophen~* Females with child-bearing potential~* Participation in a clinical trial within 4 weeks or five half-lives of exposure to an investigational drug prior to screening, whichever is longer

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Baloxavir Marboxil (Type: EXPERIMENTAL): Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
- Oseltamivir (Type: ACTIVE_COMPARATOR): Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy~* Have failed, refused, or have been deemed ineligible for standard therapy~* Measurable disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70~Exclusion Criteria:~* Primary diagnosis of lymphoma or central nervous system (CNS) malignancy~* History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years~* Evidence of active cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin 1.8 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
- Brentuximab vedotin 2.4 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
- Brentuximab vedotin 1.2 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with severe Peripheral Artery Occlusive Disease defined as Rutherford's Grade III, category 5 or 6, or Fontaine's stage IV.~* Trophic lesions with no signs of healing (no reduction in ulcer size or depth) for at least 2 weeks prior to first study treatment administration (Day 1).~* Patients with objective evidence of peripheral vascular disease (resting ankle pressure \< 70 mmHg and/or toe pressure \< 50 mmHg, and/or resting ankle-brachial index (ABI) \< 0.4 and/or resting toe-brachial index (TBI) \< 0.3 and/or metatarsal pulse volume recording (PVR) flat or barely pulsatile) in the diseased limb on two consecutive examinations performed at least 1 week apart.~* Demonstration or documentation (historical data not older than 6 months prior to first study treatment administration) of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries as assessed by angiography.~* Life expectancy \> 6 months from the first study treatment administration.~* Poor/not candidates for revascularization (patients suitable for revascularization but with a high risk of failure/ amputation/ or patients not suitable for revascularization).~Exclusion Criteria:~* Previous or current history of malignant disease. Patients who had successful tumor resection or radio-chemotherapy more than 5 years prior to inclusion in the study and no recurrence will be allowed for inclusion.~* Suspicion of malignant disease (abnormal X ray,positive. stool hemoccult, positive Prostate Specific Antigen , abnormal mammography, papanicolaou smear of Class IV or Class V characterization.~* Lower extremity surgery : bypass/angioplasty of the leg to be treated within 2 months prior to the first administration of study treatment (Day 1).~* Active proliferative retinopathy.~* Buerger's disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals age 18 and older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory (MINI). The investigators will use a DSM-5 concordant version of the MINI if it is available at the time that the first study participant is enrolled.~* Individuals who are currently or have been recently homeless (within the past 12 months) as per revised federal definition of homelessness (Homeless Emergency Assistance and Rapid Transition to Housing. In: Development DoHaU, ed2011.)~* Known to have medication treatment adherence problems as identified by the Treatment Routines Questionnaire (TRQ, 20% or more missed medications in past week or past month)~* Ability to be rated on psychiatric rating scales.~* Willingness to take long-acting injectable medication~* Currently in treatment at a Community Mental Health Clinic (CMHC) or other treatment setting able to provide mental health care during and after study participation~* Able to provide written, informed consent to study participation.~Exclusion Criteria:~* Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment.~* Prior or current treatment with clozapine~* Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial~* Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist~* Immediate risk of harm to self or others~* Female who is currently pregnant or breastfeeding~* Individual who is already in permanent and supported housing that includes comprehensive mental health services (i.e. Housing First)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAE-L (Type: EXPERIMENTAL): Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected pregnant women between 16-28 weeks' gestation~* Viable singleton pregnancy~* On or eligible for cARTs and CTX~* A resident of the study area~* Willing to adhere to scheduled and unscheduled study visit procedures~* Willing to deliver in a study clinic or hospital~* Provide written informed consent~Exclusion Criteria:~* Multiple pregnancies (i.e. twin/triplets)~* HIV-negative or HIV status unknown~* Known heart ailment~* Severe malformations or non-viable pregnancy if observed by ultrasound~* Participants with advanced HIV-disease at WHO clinical stage 3 and 4~* Confirmed or suspected TB infection,~* Unable to give consent~* Known allergy or contraindication to any of the study drugs

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CTX-alone (Type: PLACEBO_COMPARATOR): Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
- CTX-DP (Type: EXPERIMENTAL): Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age~* Underwent repeat or primary C-section~* Literate in English Language~Exclusion Criteria:~* Complicated cesarean section including cesarean hysterectomy, bowel injury, bladder injury, and/or take-back~* History of opioid use disorder and/or on chronic opiates in pregnancy~* Contraindications to NSAIDS or acetaminophen

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Educational Video Recipients (Type: EXPERIMENTAL): Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
- Standard of Care Recipients (Type: ACTIVE_COMPARATOR): Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and over~* SARS-CoV2 Infection confirmed by PCR~* Patients who do not require immediate hospitalization~* Signed informed consent~Non-Inclusion criteria:~* Patients with HIV or Hepatitis B~* Symptoms suggestive of a SARS-CoV2 infection that has been progressing for more than 7 days~* Asympomatic patients with unknown date of infection or date of infection\>7 days~* Chronic HCV infection~* Contraindication to the use of TDF/FTC~* Hypersensitivity to tenofovir, to emtricitabine or to any of the excipients (especially lactose)~* Glomerular filtration rate \<80mL / min~* Recent (less than 7 days) or concomitant use of NSAIDs or other nephrotoxic drugs (antiinfectives, immunosuppressants, allopurinol, lithium~* need for hospitalization for contemporary decompensation of a comorbidity~* need for hospitalization due to SARS-CoV2 infection:~* Capillary oximetry less than 95%~* clinical evaluation by the investigating doctor leading to hospitalization~* Pregnant or breastfeeding women~Exclusion Criteria:~- Diagnosis of pregnancy during treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TDF / FTC (Type: EXPERIMENTAL): 2 tablets on Day-1 then 1 tablet/day for 6 days
- usual care (Type: NO_INTERVENTION): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: StriveWeekly Online Mental Health Trial Post-pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* enrolled as a student at Harvard College (academic year 2021-2022)~Exclusion Criteria:~* invalid data reporting (e.g., straight-lined responses to surveys)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Immediate Intervention Condition (Type: EXPERIMENTAL): Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
- Waitlist Condition (Type: NO_INTERVENTION): Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete